Vaccine drug against colibacteriosis

FIELD: medicine; biotechnologies.

SUBSTANCE: vaccine drug includes deactivated Escherichia coli bacteria of strain No 389 (078) and auxiliary substances. Additionally the drug includes aminoethylethyleneimine and liposome-forming mix as auxiliary substance at the following component rate in fluid form, wt %: aminoethylethyleneimine - 0.5-3; liposome-forming mix - 7.3-15; suspension of deactivated Escherichia coli bacteria of serotype 078 - 82.0-91.5.

EFFECT: harmless for fowl, enhanced antigenic and immunogenic activity.

3 cl, 4 tbl, 6 ex

 

The invention relates to the field of veterinary medicine, in particular to poultry, namely vaccines against infectious diseases, namely against colibacillosis.

Colibacteriosis (colisepticaemia, alienface, colibacillosis) - enzootic septic disease of various types of poultry (mainly chickens, ducks, geese), caused by pathogenic types of E. coli of different serological groups. Clinically colibacteriosis is manifested by depression, loss of appetite, diarrhea, difficulty breathing, wheezing or termination of oviposition. At postmortem autopsy noted pericarditis, perihepatitis, aerosakkulit, salpinges, ovaria, peritonitis. The disease causes significant economic losses to the poultry industry.

Now for the prevention and treatment of infectious diseases is widely used antibiotics, sulfa, nitrofuranovye and a variety of complex drugs. In particular, for the prevention and treatment of colibacillosis recommended oxytetracycline, tetracycline, biovet, levomycetin, tetrachloride, salvagin, ftazin, biofuel and a number of other medicines (Veterinary drugs: a Handbook / Comp. Lupaland and other M, Agropromizdat, 1988, pp.5-33; Novels E.A. Biological veterinary drugs in Russia: vaccines, serum-based assays: a Handbook. - Statalist is about: K.: RUTIN, 2005, s).

The disadvantages of most drugs is low efficiency, especially to address preventive tasks, a large number of contraindications, the high cost of drugs.

In the prevention of colibacillosis the main role plays the strict performance of a complex of organizational, economic, appropriate and veterinary-sanitary measures, however, an important role for specific prophylaxis. The most effective way of dealing with the veterinary infections is vaccination of livestock infected herds.

Currently, there are a significant number of live and inactivated vaccines, usually mono - or divalent intended for the prevention of certain infectious diseases, such as Newcastle disease, reovirus birds etc. (EP 0100752; EP 0044920; US 4515777; US 4302444; Negribetsky, Usermanual and other Vaccines as an object of the invention, M, unuigbe, 1988, s-229). More convenient polyvalent vaccine drugs for the protection of livestock simultaneously from several viral diseases have not yet found wide application because the creation of such drugs is very time consuming due to the necessity of taking into account the interaction of components of vaccines and antibodies that occur in the body of the vaccinated animal or poultry at their introduction.

the particular known vaccine against colibacillosis birds (SU 1792330)obtained by cultivation of a strain of Escherichia coli (E. coli), followed by inactivation of the cells with acetone and the allocation of the resulting sludge. The lack of a vaccine is its low efficiency and a high probability of infection of birds surviving bacterial cells.

Closest to the claimed vaccine composition and the achieved effect is inactivated vaccine (TU 10-19.68-89), representing the fine white suspension containing formalin inactivated bacteria Escherichia coli serotype 078 mixed with adjuvant on the basis of aluminium hydroxide (GOA formulatin). Vaccination is carried out by a single injection in the breast or thigh muscle in a volume of 0.5 ml all healthy birds at the age of 28-32 days.

The disadvantages of this vaccine are not high enough antigenic and immunogenic activity, as well as the possibility of occurrence of inflammatory reactions at the site of its introduction and subsequent development of granulomas and abscesses.

The technical problem to be solved in the framework of the present invention was to create a more effective vaccine against colibacillosis.

The technical result was achieved by the creation of a vaccine, which is a composition comprising a liquid form of the following ingredients, wt.%:

aminoethylethanolamine (AAAI)0,5-3,0;
liposomally mixture (LOS)7,3-15,0;
suspension of inactivated bacteria E. coli serotype 07882,0-91,5.

Additionally, the drug is designed to further drying may contain chloroform or other solvent.

Received vaccine formulation is a suspension of liposomes containing a mixture of inactivated antigen of the bacterium Escherichia coli strain No. 389 (078) aminoethylethanolamine enclosed in liposomal vesicles. Instead of the strain E. coli No. 389 (078) can be used and a different strain of E. coli that causes colibacteriosis.

In the basis of the proposed new vaccine was founded assumption that the treatment of the bacterial cells by aminoethylethanolamine possible, on the one hand, to exclude the presence in the vaccine of living organisms, and on the other hand, due to the destruction of cells increased content in the suspension of the antigen, which increases its effectiveness. However, the introduction into the composition of liposomes provides the location of the active material in vesicles, collapsing directly into the body of the animal that provides the maximum concentration of antigen in the area of introduction and accordingly an increased production of antibodies by the body of vaccinated birds.

And the use of AEEI at a concentration of less than 0.5 wt.% reduces vaccine efficacy and increases the risk of the presence of live bacteria, provides increased concentrations of more than 3%, without affecting the concentration of the antigen, making the vaccine more toxic.

The nature of the used FOX on antibody production has virtually no effect. So, as FOX used industrially manufactured as individual phospholipids, and mixtures thereof, derived from vegetable, animal or biotechnological raw material; a mixture of phospholipids and dry fillers (sugars, polyols, salts) according to the technology described in EN 2130771, or a mixture containing phospholipids, with 10-12% sugar and 1% to 3% water-soluble polymers previously used in the patent authors (EN 2169581, EN 012968). The nature of the used liposomes on antibody production has virtually no effect.

The content of LYS concentration of greater than 15 wt.% increases the viscosity of the drug in concentrations of less than 7.3 per cent does not ensure the completeness of the space of antigen in vesicles and affects its stability during storage.

Vaccination of birds using the inventive vaccine is the introduction above liposomal vaccine into the body of the bird parenterally, intramuscularly in the breast or thigh muscle.

Typically, the indication for the use of the vaccine is unsafe management of the above infections. Vaccinium all clinically healthy birds at the age of 28-32 days. The drug is administered intramuscularly in the breast or thigh muscle in dose is 0.5 ml per 1 head.

The essence and practical applicability of the claimed invention are illustrated by the following examples.

EXAMPLE 1. The vaccine was prepared by the following method. 0.45 l of cell suspension of Escherichia coli strain No. 389 (078) with a concentration of 2×1010CFU/cm3obtained from VGNKI, mixed at a temperature of 37°With constant stirring with 50 ml of 20% solution AAAI within 20 minutes the resulting preparation contained antigens and did not contain viable cells of bacteria.

20 ml of the preparation containing the antigens were mixed with 2.0 g of total phospholipids of vegetable lecithin, 0.5 g of butylacetate and 0.5 g of lactose. The mixture is homogenized for 10 minutes at speed 700g and the temperature of the mixture 22-24°C.

Liquid vaccine in 1 ml contained 1.5×1010cells of Escherichia coli strain No. 389 (078); 0.002 g AAAI, 0.14 g LOS.

Example 2. The vaccine was prepared by the following method. 0.475 litres of suspension cells of Escherichia coli strain No. 389 (078) with a concentration of 2×1010CFU/cm3obtained from VGNKI, mixed at a temperature of 37°With constant stirring with 25 ml of 20% solution AAAI within 20 minutes the resulting preparation contained antigens and did not contain viable cells.

20 ml of the suspension containing the antigens, 1.2 g of total phospholipids from sunflower seeds, 0.8 g of sorbitol and 5.0 g of chloroform were placed in hermetically closing the I capacity of 30 cm, at a temperature of 37°C. Drying was performed under vacuum for 1 hour at a temperature of 37°and With constant stirring speed of 50 rpm was obtained 2.1 g of dry fine powder with a moisture content of 0.7%, containing 2×1011cells of Escherichia coli strain No. 389 (078); 0.2 g AAAI, 1.8 g LOS.

For vaccination of 0.5 g of liposomal drug was dissolved in 10 ml distilled water.

Example 3. The vaccine was prepared by the following method. 1.0 l of cell suspension of Escherichia coli strain No. 389 (078) with a concentration of 2×1010CFU/cm3obtained from VGNKI, mixed at a temperature of 37°With constant stirring with 150 ml of 20% solution AAAI within 20 minutes the resulting preparation contained the antigen and did not contain viable bacteria.

20 ml of the preparation containing the antigens were mixed with 1.0 g of total phospholipids from sunflower seeds, 0.6 g of sorbitol and 5.0 g of chloroform in the hermetically sealable vessel with a volume of 150 cm, at a temperature of 37°C. the Container was closed and pumped out the air before reaching the vacuum of 0.3 ATM and withstood the mixture for 1 hour at a temperature of 37°and With constant stirring speed of 50 rpm was received 15 ml of concentrate containing 2.0 g of liposomal vesicles.

To 100 volumes of concentrate liposomal vesicle antigens were added to 5 volumes of 20% aqueous rest the RA gelatin and 50 volumes of 20% sucrose solution. The resulting mixture was thoroughly mixed and poured into trays with a layer thickness of 3.0-10.0 mm, closed the lid and carried on the shelves of the freeze chamber. The material was frozen to a temperature of 30 to 40°C and held at this temperature for 2-3 hours, after which the chamber was evacuated at 120-130 mm Hg In further shelves was heated up to +24°With a speed of 4 deg/hour. The total drying time was 42-46 hours. For vaccination of 0.5 g of liposomal drug was dissolved in 10 ml distilled water.

EXAMPLE 4. The vaccine was prepared according to the method of example 1. 0.43 l cell suspension of Escherichia coli strain No. 389 (078) with a concentration of 2×1010CFU/cm3obtained from VGNKI, mixed at a temperature of 37°With constant stirring with 70 ml of 25% solution AAAI within 20 minutes the resulting preparation contained antigens and did not contain viable cells of bacteria.

20 ml of the preparation containing the antigens were mixed with 2.3 g of total phospholipids of vegetable lecithin, 0.6 g of butylacetate and 0.6 g of lactose. The mixture is homogenized for 10 minutes at a rotation speed of 700 g and the temperature of the mixture 22-24°S, and then used for immunization.

EXAMPLE 5. The vaccine was prepared according to the method of example 1. 0.489 l cell suspension of Escherichia coli strain No. 389 (078) with a concentration of 2×1010CFU/cm3,obtained from VGNC is, mixed at a temperature of 37°With constant stirring with 11 ml of 25% solution AAAI within 20 minutes the resulting preparation contained antigens and did not contain viable cells of bacteria.

20 ml of the preparation containing the antigens were mixed with 1.2 g of total phospholipids of vegetable lecithin, 0.3 g of butylacetate and 0.3 g of lactose. The mixture is homogenized for 10 minutes at a rotation speed of 700 g and the temperature of the mixture 22-24°S, and then used for immunization.

The composition of the obtained vaccine preparations (excluding changes during drying are given in table 1.

td align="center"> 82,0
Table 1
The composition of liquid vaccines
ExampleThe contents of the ingredients in the liquid mixture, wt.%
AAAILOSSuspensionThe content of the E. coli cells
11,813,884,41.5×1010
20.6* (0.9)7.5* (10,7)74,0* (88,4)1.4×1010
32.0* (2.4)6.0* (7.3)73,2* (90,3)1.3×1010
43.015.01.5×1010
50.58.091,51.5×1010
* concentration taking into account the presence in the mixture of chloroform

Example 6. The vaccine used for the prevention of colibacillosis birds in the experimental base of the St. Petersburg state Academy of veterinary medicine. The drug was administered intramuscularly in the breast or thigh muscle in a dose of 0.5 ml per 1 head.

The vaccine was tested for safety antigenic and immunogenic activity. The strength of post-vaccination immunity determined after 7, 28, 45, 60, 90 days after vaccination in agglutination reactions. The obtained test results are presented in tables 2-4.

Table 2
Evaluation of the place of administration of a vaccine against colibacillosis in example 1 within 10 days after injection.
No.VaccineResults studies
The degree of destructionTraces of vaccinesGranulomaSwelling
1Liposomal vaccinelightNot foundNot found 20
2GOA Formulatinaverage60Not found40

Table 3
Evaluation of the place of administration of a vaccine against colibacillosis in example 1 through 90 days after injection.
No.VaccineVisible changes in the areas of vaccines,%
The degree of destructionWithout visible changesNeznacit. Qty. vaccineFibrin
1Liposomal vaccinelightnot foundnot foundnot found
2GOA Formulatinaverage4060not found

Table 4.
The level of specific antibodies in the serum of vaccinated chickens (antibody titers in log2(M±m)).
No.GroupThe study, after immunization
7 28456090
1Liposomal vaccine for approx. 16,1±0.2a 9.5±0,39,9±0,29,8±0,19,8±0,2
2Liposomal vaccine 25,8±0.29,6±0,39,8±0,29,6±0,19,6±0,2
3Liposomal vaccine Prim6,0±0.29,3±0,39,6±0,29,1±0,19,1±0,2
4Liposomal vaccine Prim6,0±0.29,7±0,39,7±0,29,6±0.39,3±0,4
5Liposomal vaccine note55,9±0.29,0±0,49,2±0,29,0±0,19,1±0,2
6GOA formulatin5,4±0,57,7±0,57,4±0.57,2±0,46,8±0,3
7Controlnot foundnot foundnot OBN is hidden 0,5±0,10,7±0,1

As follows from the above results, the vaccine formulation is harmless to birds, has expressed antigenic and immunogenic activity.

1. Vaccine formulation against colibacillosis, containing in its composition inactivated bacteria Escherichia coli strain No. 389 (078) and excipients, characterized in that it further comprises aminoethylethanolamine, and as excipients lipomatous mixture in the following proportions of ingredients in liquid form, wt.%:

aminoethylethanolamine0.5 to 3
liposomally mixture7,3-15
suspension of inactivated bacteria
Escherichia coli serotype 07882,0 is 91.5

2. Vaccine formulation against colibacillosis according to claim 1, characterized in that as liposomally mixture comprises a mixture of phospholipids and fillers.

3. Vaccine formulation against colibacillosis according to claim 1, characterized in that as liposomally mixture comprises a mixture of phospholipids, sugars and water-soluble polymers.



 

Same patents:

FIELD: medicine; veterinary.

SUBSTANCE: medicine includes metal iodine and potassium iodide, prolongator and water. 1,2-propylene glycol is used as prolongator, and additionally vitamin A (retinol acetate), vitamin E (alpha-tocopherol acetate), vitamin B1 (thiamine hydrochloride), vitamin B2 (riboflavin), vitamin B6 (pyridoxine hydrochloride), vitamin B12 (cyanocobalamin), iron carbonate, magnium phosphate, manganese sulfate, copper sulfate, zinc sulfate, cobalt chloride, sodium chloride, amber acid, glucose, rectified ethyl alcohol (96%) are applied. Medicine components are taken at the following rate, g/100 ml of distilled water: metal iodine, chemically pure 0.112-0.187; potassium iodide, R 0.337-0.562; vitamin E (alpha-tocopherol acetate) 0.060-0.100; vitamin A (retinol acetate) 3.750-6.250 thousand mass units; vitamin B1 (thiamine hydrochloride) 0.052-0.087; vitamin B2 (riboflavin) 0.037-0.062; vitamin B6 (pyridoxine hydrochloride) 0.034-0.056; vitamin B12 (cyanocobalamin) 0.026-0.044; iron carbonate, R 0.337-0.562; magnium phosphate, R 0.337-0.562; manganese sulfate, R 0.172-0.287; copper sulfate, R 0.090-0.150; zinc sulfate, R 0.315-0.525; cobalt chloride, R 0.071-0.119; sodium chloride, R 0.589-0.981; amber acid, primary standard 0.225-0.375; glucose, AR 0.172-0.287; rectified ethyl alcohol (96%) 0.300-0.500 ml; 1,2- propylene glycol 0.900-1.500 ml. Method involves medicine administration with fodder in dosage of 1.00-1.50 mg per 1 kg of fish weight once per day for 5-7 days.

EFFECT: correction of needs for bioactive substances, prevention of avitaminosis, achievement of high antioxidant organism protection level, prevention of accumulation of non-saturated fatty acid peroxides harmful to fish.

2 cl, 3 tbl, 3 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention is used for treatment of bacteriemic infections, it is prepared as composition in the form of dry powder, adapted for delution by water with reception of the suspension important pH in a range from approximately 5.0 to approximately 5.5 at initial delution and which in addition contains the stabilizer pH which represents sodium-carboxymethyl cellulose. Besides, the invention concerns application sodium-carboxymethyl cellulose for reduction of degree of degradation clavunalate and for stabilisation pH the received suspension.

EFFECT: stability improvement in preparation.

7 cl, 1 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: method is implemented as follows: bacterial-enzymatic probiotic "Balance-narine-f" is introduced locally and orally in combination with inhalation of negative air ions.

EFFECT: allows for decrease of complications and higher efficiency of treatment.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: sterile aqueous inhalation solution containing active substance Tobramycine. Preparation of invention is offered with high content of active substance (approximately 80 to 120 mg/ml Tobramycine). Preparation also contains acid adjuvant and has low content of sodium chloride (maximum approximately 2 mg/ml). Preparation can be injected or introduced as aerosol with e.g. common sprays.

EFFECT: suitable for application in combination with recent sprays with vibrating membrane and gives the chance for application of an individual therapeutic dose.

24 cl, 1 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: antibacterial and rehydration therapies are combined with prescribed sorbents, symptomatic therapy. From first day of disease prescribed is infusion herb collection consisting of silverweed rhizome, salvia leaves, milfoil herb, St. John's wort herb, inula rhizomes with roots, tickseed herbs, mint leaves, fennel fruits and buckthorn bark at ratio of components 2:2:2:2:2:2:2:2:1. Infusion is taken up dosed 1\3 glass 3 times a day, 30 min before meal within 10 days. Then within three weeks after basic therapy appoint infusion from silverweed rhizome, salvia leaves, milfoil herb.

EFFECT: provides accelerated normalisation of clinical-laboratory indicators, and prevention of infectious complications without by-effects.

2 cl, 1 tbl, 1 ex

FIELD: medicine; biotechnologies.

SUBSTANCE: strain Lactobacillus casei FERM BP-100059 (FERM P-19443), possessing probiotic properties; grow up in the presence of any from one to four amino acids as a source of the nitrogen necessary for growth. At planting in suitable cultural to medium, the final value pH makes 4.0 or lower, and the highest acidity makes 1.5% or above. The strain resistable is to 5% salts of cholic acids. The strain produces an antibiotic. On the basis of the strain as the active beginning, the lactobacillus preparation of probiotic action for humans, animals and plants and the preventive or therapeutic agent against human, animal and plant infections.

EFFECT: ability to colonise and breed in the centres chronic the infections, steady against treatment, strong clearing action and destruction causing a bacterium infection.

12 cl, 5 dwg, 56 tbl, 34 ex

FIELD: medicine; pharmacology.

SUBSTANCE: peroral pharmaceutical dosed out form for treatment of the conditions bound to secretion of acid in a stomach, includes an acid-sensible inhibitor of the proton pump and antagonist of H2-molecular switchers, with the delayed and-or prolonged liberation of the proton pump acid-sensible inhibitor, and fast liberation of antagonist of H2-molecular switchers.

EFFECT: maximum suppression of acid in a stomach after the first dose and throughout all course of treatment.

69 cl, 4 dwg, 7 ex

FIELD: medicine; veterinary science.

SUBSTANCE: vaccine includes inactivated adhesive antigens E.coli K88, E.coli K99, E.coli F-41, E.coli 987P and an adjuvant - aluminum hydrate. As the inactivated adhesive antigens E.coli use inactivated filamentous adhesive antigens E.coli K88 ab, E.coli K88 ad, E.coli K88 ad, E.coli K99, E.coli F-41, E.coli Att-25, E.coli 987P with activity level in reaction of the passive hemagglutination peer as 1:2048-4096; 1:1024-2048; 1:256-512; 1:1024-2056; 1:1024-2056; 1:32-64; 1:256-512, accordingly, at a following parity of components, wt. %: inactivated filamentous adhesive antigens E.coli K88 ab, E.coli K88 ad, E.coli K88 ad, E.coli K99, E.coli F-41, E.coli Att-25, E.coli 987P, taken in mass parities 1:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2, accordingly - 55-65, 5.8-6.2%-s' aluminium hydrate the rest.

EFFECT: rising of safety of livestock of agricultural animals.

2 cl, 1 tbl, 8 ex

FIELD: medicine; pharmacology.

SUBSTANCE: perform processing of an elevated part and roots of the primrose plant (Primula macrocalyx Bge.) with an organic dissolvent - ligroin or hexane with the subsequent extraction with acetone and allocation of a target product using chromatography.

EFFECT: increase of output of the product.

4 ex, 2 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: system of delivery of medicinal substance includes one department consisting from (i) of a kernel from thermoplastic polymer, filled with medicinal substance, (ii) an intermediate layer from the thermoplastic polymer filled with medicinal substance, and (iii) covers from the thermoplastic polymer, covering an intermediate layer and not containing medicinal substance, where the specified intermediate layer is filled (a) with crystals of the first pharmacologically active substance, and (b) the second pharmacologically active substance in the dissolved form and where the kernel is filled specified to the second pharmacologically active substance in the dissolved form. The delivery system is intended for vaginal introduction of the medicinal substance.

EFFECT: possibility of adjustment of rate of liberation of two or more active ingredients irrespective of others, at maintenance of long physical stability of system at room temperature.

51 cl, 21 dwg, 10 tbl, 4 ex

FIELD: medicine; veterinary science.

SUBSTANCE: vaccine includes inactivated adhesive antigens E.coli K88, E.coli K99, E.coli F-41, E.coli 987P and an adjuvant - aluminum hydrate. As the inactivated adhesive antigens E.coli use inactivated filamentous adhesive antigens E.coli K88 ab, E.coli K88 ad, E.coli K88 ad, E.coli K99, E.coli F-41, E.coli Att-25, E.coli 987P with activity level in reaction of the passive hemagglutination peer as 1:2048-4096; 1:1024-2048; 1:256-512; 1:1024-2056; 1:1024-2056; 1:32-64; 1:256-512, accordingly, at a following parity of components, wt. %: inactivated filamentous adhesive antigens E.coli K88 ab, E.coli K88 ad, E.coli K88 ad, E.coli K99, E.coli F-41, E.coli Att-25, E.coli 987P, taken in mass parities 1:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2, accordingly - 55-65, 5.8-6.2%-s' aluminium hydrate the rest.

EFFECT: rising of safety of livestock of agricultural animals.

2 cl, 1 tbl, 8 ex

FIELD: medicine, microbiology.

SUBSTANCE: invention concerns nucleotide sequence coding TolC, and also to certain amino-acid sequence which is built in in permissive, located from lateral aspect of a membrane area of TolC. In the invention is described a plasmid, containing a nucleotide sequence, for an expression of the merged protein or merged peptide. The invention concerns also the transformed bacterium, in particular enterobacteria, to its use as a part of a pharmaceutical composition for stimulation of the immune response and in a diagnostic set for detection of interesting substance in an organism. The framed transport system provides high efficiency of presentation of a product of an expression in an external cellular membrane of a bacterium.

EFFECT: provision of high efficiency of presentation of product of expression in external cellular membrane of a bacterium.

13 cl, 1 dwg, 5 ex

FIELD: veterinary.

SUBSTANCE: escherichia coli cells containing adhesive gene K 88 ab, K 88 ac, K 88 ad, K 99, F-41, Att-25, 987P are cultivated in liquid nutrient medium to produce vaccine. Physical, chemical and biological indicators are investigated in the process of bacterial bulk growth. In addition, activity of fimbrial adhesin in passive hemagglutination of cellular bacterial bulk is determined. Further cultivation is terminated when fimbrial adhesins titers values are K 88 ab, K 88 ac, K 88 ad, K99, F-41, Att-25, 987P equal to: 1:2048-4096; 1:1024-2048; 1:256-512; 1:1024-2056; 1:1024-2056; 1:32-64; 1:256-512, accordingly. Biological bulk is then concentrated and spinned at 3000-5000 rev/min for 20-25 minutes to separate culture broth from cellular bacterial bulk. Then vaccine is inactivate.

EFFECT: improvement of target product quality.

2 tbl, 5 ex

FIELD: veterinary medicine.

SUBSTANCE: it is necessary to select the affected organs from dead nutrias out of local epizootic focus, prepare the suspension out of pathological material to inoculate onto differential-diagnostic media, isolate pure cultures of Escherichia coli, Salmonella typhimurium, Streptococcus pneumoniae and Streptococcus fecalis, grow separately the isolated cultured in beef-extract nutritive medium at addition of 0.2%-glucose to achieve the concentration of microbial cells of about 4-5 bln/cu/ cm, inactivate with formalin up to 0.4-0.6%-final concentration, keep at 37°C for about 72-96 h, mix the cultures at equal ratios, add 3%-aluminum hydroxide solution at the quantity of 20% against the volume of the culture to be thoroughly mixed. Then the vaccine obtained should be packed and sealed. The innovation is simple in usage, moreover, it enables to increase specificity and immunogenicity of the obtained vaccine.

EFFECT: higher efficiency.

1 tbl

FIELD: veterinary medicine.

SUBSTANCE: the vaccine suggested contains as antigens: the cell suspension of pure cultures of Escherichia coli, Salmonella typhimurium and Streptococcus fecalis obtained due to selecting the affected organs from dead nutrias out of local epizootic focus, preparing the suspension, inoculation onto differential-diagnostic media, isolating pure cultures of the agents of Escherichia coli, Salmonella typhimurium and Streptococcus fecalis. The obtained pure cultures of microorganisms should be separately grown in beef-extract broth with glucose up to the concentration of microbial cells being 4-5 bln/cu. cm to be then mixed at equal ratios. The vaccine, also, contains formalin, glucose and aluminum hydroxide at the following ratio of the components, weight%: cell suspension of Escherichia coli pure culture isolated from the affected organs out in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0; cell suspension of Salmonella typhimurium pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0, cell suspension of Streptococcus pneumoniae pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu/ cm 18.0-21.0 cell suspension of Streptococcus fecalis pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0, glucose 2.0-1.0; formalin 2.0-1.5; aluminum hydroxide - the rest. The vaccine in question is of high specificity, safety and immunogenicity.

EFFECT: higher efficiency.

5 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: down-calving cows should be immunized simultaneously with vaccine "Coli-Vac C99" and formulated alum vaccine against salmonellosis in calves at 10-d-long interval 1.5 mo before calving. The first dosage corresponds to 10 cu. cm, the second one - 15 cu. cm. Simultaneously with vaccination it is necessary to inject Ligavirin for cows at the dosage of 5 ml/cow. As for calves born in these cows they should be once injected intramuscularly with Ligavirin for 0.5-1 h after their birth at the dosage of 1 ml/calf. The innovation enables to create more tense specific immunity in cows before calving and colostral immunity in calves born in these cows.

EFFECT: higher efficiency of prophylaxis.

3 ex, 5 tbl

FIELD: medicine, pediatrics, otorhinolaryngology.

SUBSTANCE: the present innovation deals with conservative treatment and rehabilitation in children in case of chronic adenoiditis (CA) and in ARVI-suffering ones. It is necessary to isolate the following groups of patients: with CA and purulent exudates, at CA at the background of allergic rhinitis and at CA at the background of intracellular infections. One should carry out conservative therapy along with washing a patient's nasopharynx and differentiated therapy for each group of patients. Therapy includes the intake of mucoregulating preparations, and differentiated therapy for patients with CA and purulent exudates additionally includes local antibacterial therapy with applying Bioparox for 7 d. For patients at CA at the background of allergic rhinitis - application of local antihistamine preparations or mast cells stabilizers. For patients at CA at the background of intracellular infections - two courses of systemic antibacterial therapy with macrolides and Bioparox locally followed by introducing interferonogens or interferon inductors. In about 7-8 d after the onset of therapy course all the patients should undergo 10 seances of quantum therapy with "Rikta" apparatus along with the intake of antioxidants, 4 times annually it is important to conduct rehabilitation with IRS-19, with biopreparation "Narine" endonasally for 10 d, inside - bifidumbacterin per 3 wk by alternating with "Narine". The innovation provides individual curative program for patients with CA of different groups at stable clinic effect of decreased hypertrophy of pharyngeal tonsil up to degree I and restoring microbiocenosis and values of local immunity in nasopharynx.

EFFECT: higher efficiency of therapy.

2 tbl

FIELD: medicine.

SUBSTANCE: method involves intranasally administering immunomodulator preparation of bacterial origin with one dose placed in each nasal passage twice a day during 14 days repeated in obligatory way every 3 months during one year.

EFFECT: stable repair of injured immunity chains; hindered fixation and reproduction of pathogenic organisms.

FIELD: medicine.

SUBSTANCE: method involves making instillations and applications with Cholisal gel 2-3 times a day. Imudon is introduced at a dose of 6 pills a day during 20 days. Polysorb MP is introduced at a dose of 1 tea spoon diluted with 100 ml of water once a day during 20 days.

EFFECT: enhanced immunotropic, detoxifying effectiveness together with bactericide and anti-inflammatory action; increased organism resistance.

3 tbl

FIELD: veterinary microbiology, biotechnology.

SUBSTANCE: the innovation deals with developing live avirulent vaccine against colibacteriosis in calves for intramuscular injection, being simple in manufacturing and application. The vaccine is being the suspension and contains an antigen "B-5" out of E. coli strain as an antigen at the content of 1.0x1010-1.2x1010 microbial cells/cu. cm physiological solution. The vaccine is avirulent, nonreactogenic and safe.

EFFECT: higher efficiency of application.

5 ex, 4 tbl

FIELD: veterinary microbiology.

SUBSTANCE: invention proposes the strain Escherichia coli B-5 that produces thermolabile toxin eliciting immunogenic properties being without pathogenic property.

EFFECT: valuable properties of strain.

1 ex

Up!